Skip to main content

Table 2 Breast cancer mortality risk by hormone receptor status among women of different diagnosis age, race/ethnicity, diagnosis year, tumor stage, grade, histology, and axillary lymph node positivitya

From: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

  ER+/PR+ ER+/PR- ER-/PR+ ER-/PR-  
  (n = 98,463) (n = 19,886) (n = 4,896) (n = 31,930)  
Characteristics No. at risk No. deaths HR No. at risk No. deaths HR 95% CI No. at risk No. deaths HR 95% CI No. at risk No. deaths HR 95% CI p value for interaction
All casesb 98,463 7,319 1.0 19,886 2,434 1.4 1.3–1.5c 4,896 848 1.8 1.6–1.9c 31,930 6,300 2.3 2.2–2.4c  
Age at diagnosis, yearsd                 
   <50 16,962 1,042 1.0 2,387 245 1.2 1.1–1.4c 1,430 209 1.6 1.4–1.9c 8,056 1,323 2.1 1.9–2.3c  
   50–64 23,467 1,104 1.0 4,745 416 1.5 1.3–1.7c 1,072 124 1.5 1.2–1.8c 7,651 1,214 2.3 2.1–2.5c  
   ≥65 25,078 1,496 1.0 5,563 540 1.5 1.3–1.7c 718 119 2.1 1.8–2.6c 5,536 1,020 2.6 2.4–2.8c 0.03
Diagnosis yeare                 
   1990–1992 8,298 1,285 1.0 1,889 419 1.3 1.2–1.5c 597 146 1.6 1.3–1.9c 2,850 831 1.7 1.5–1.9c  
   1993–1995 13,665 1,348 1.0 2,688 428 1.5 1.3–1.7c 944 160 1.5 1.2–1.8c 4,859 1,234 2.2 2.0–2.4c  
   1996–1998 19,350 837 1.0 3,493 282 1.5 1.3–1.7c 971 121 2.1 1.7–2.6c 6,181 1,059 2.8 2.5–3.1c  
   1999–2001 24,194 172 1.0 4,625 69 1.6 1.2–2.1c 708 25 3.6 2.3–5.1c 7,353 433 4.9 4.1–6.0c <0.001
Race/Ethnicityf                 
   Non-Hispanic white 53,397 2,831 1.0 10,187 916 1.5 1.3–1.6c 2,396 313 1.8 1.6–2.0c 15,371 2,462 2.3 2.2–2.5c  
   African-American 3,536 348 1.0 907 125 1.2 1.0–1.5c 293 60 1.7 1.3–2.2c 2,734 615 2.2 1.9–2.6c  
   Native American 196 19 1.0 34 11 1.5 0.5–3.8 12 1 1.7 0.1–16.4 102 25 3.4 1.5–7.3c  
   Asian/Pacific Islander 4,497 189 1.0 748 63 1.8 1.3–2.4c 267 34 1.6 1.1–2.4c 1,273 166 2.3 1.8–2.8c  
   Hispanic white 3,881 255 1.0 819 83 1.3 1.0–1.7c 252 44 1.9 1.3–2.6c 1,763 289 2.3 1.9–2.8c 0.77
Tumor stageg                 
   I 33,821 487 1.0 6,038 146 1.4 1.2–1.7c 1,369 51 1.6 1.2–2.1c 7,704 391 2.3 2.0–2.7c  
   II 27,363 2,110 1.0 5,472 674 1.4 1.3–1.6c 1,529 248 1.6 1.4–1.9c 11,051 2,069 2.3 2.2–2.5c  
   III 3,410 659 1.0 922 252 1.3 1.2–1.6c 245 104 2.1 1.7–2.6c 1,940 763 2.3 2.0–2.6c  
   IV 672 302 1.0 192 102 1.3 1.0–1.6c 59 42 1.9 1.3–2.7c 357 245 2.3 1.9–2.8c 0.45
Tumor size (cm)h                 
   0–1.9 39,418 865 1.0 6,957 243 1.4 1.2–1.6c 1,607 91 1.5 1.2–1.9c 8,799 715 2.6 2.3–2.9c  
   2–5 22,579 2,081 1.0 4,781 708 1.5 1.3–1.6c 1,331 253 1.8 1.5–2.0c 10,214 2,019 2.2 2.1–2.4c  
   >5 2,718 526 1.0 761 206 1.3 1.1–1.6c 217 89 2.2 1.7–2.7c 1,730 636 2.2 1.9–2.5c <0.001
Axillary lymph node statusi                 
   Negative 42,451 942 1.0 7,924 324 1.6 1.4–1.8c 1,898 114 2.0 1.6–2.4c 12,541 1,006 2.8 2.6–3.1c  
   1–3 14,953 1,021 1.0 2,828 324 1.5 1.3–1.7c 790 133 1.8 1.5–2.1c 4,857 977 2.5 2.3–2.7c  
   4–10 5,313 861 1.0 1,133 277 1.4 1.2–1.6c 332 108 1.7 1.3–2.1c 2,268 793 2.4 2.2–2.7c  
   ≥11 2,549 734 1.0 739 249 1.2 1.0–1.4c 182 90 1.7 1.3–2.1c 1,386 692 2.2 1.9–2.4c 0.08
Tumor histologyj                 
   Ductal 52,178 2,919 1.0 9,978 994 1.5 1.4–1.6c 2,711 390 1.8 1.6–2.0c 18,542 3,040 2.3 2.2–2.5c  
   Lobular 3,975 186 1.0 938 64 1.4 1.0–1.9c 123 3 0.4 0.1–1.4 325 47 1.9 1.4–2.7c  
   Ductal/Lobular 5,472 254 1.0 929 59 1.3 0.9–1.7 148 13 1.1 0.6–2.0 511 83 2.7 2.1–3.5c  
   Inflammatory 241 52 1.0 77 22 1.4 0.8–2.3 39 19 3.4 1.9–6.1c 258 123 3.5 2.4–5.0c  
   Comedo 652 91 1.0 187 19 0.6 0.4–1.1 91 16 1.2 0.7–2.1 556 109 1.6 1.2–2.1c  
   Medullary 120 14 1.0 73 6 0.7 0.2–2.2 48 4 0.9 0.2–3.0 716 54 0.7 0.4–1.4 <0.001
Tumor gradek                 
   1 13,854 156 1.0 2,141 40 1.6 1.1–2.3c 310 6 1.0 0.4–2.5 661 32 2.6 1.7–3.9c  
   2 32,661 1,349 1.0 5,555 374 1.5 1.3–2.1c 1,074 95 1.7 1.3–2.1c 4,312 575 3.1 2.8–3.4c  
   3 17,352 1,873 1.0 4,613 710 1.3 1.2–1.5c 1,694 319 1.7 1.5–1.9c 14,967 2,635 2.1 1.9–2.2c  
   4 1,399 180 1.0 315 50 1.4 1.0–2.0c 124 25 2.1 1.4–3.3c 1,112 226 2.3 1.8–2.8c <0.001
  1. aThe reference ER/PR profile for all analyses was ER+/PR+. bHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). c p < 0.05. dHRs adjusted for year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). eHRs adjusted for age at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). fHRs adjusted for age and year at diagnosis, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). Race unknown, n = 3,185. gHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status (categorical), and surgical and radiation treatment. Stage unknown, n = 4,728. hHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status (categorical), and surgical and radiation treatment. Size unknown, n = 7,196. iHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, grade, and surgical and radiation treatment. Nodal status unknown, n = 22,394. jHRs adjusted for age and year at diagnosis, race, SEER registry, tumor grade, stage, lymph node status (categorical), and surgical and radiation treatment. Other/unknown histology, n = 7,155. kHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, lymph node status (categorical), and surgical and radiation treatment. Grade unknown, n = 24,544. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.